The Annual European Society for Medical Oncology (ESMO) 2020 Congress was held virtually from September 19 to September 21, 2020 due to the COVID-19 pandemic. Conference highlights include the first numerical results for ipatasertib in prostate cancer, data from the LEAP-005 study of Lenvima + Keytruda in solid tumors, updated data from KRAS inhibitor AMG 510 in non-small cell lung cancer (NSCLC), new results from the ADAURA trial of Tecentriq in NSCLC, results from the COMBI-i trial evaluating the investigational immunotherapy spartalizumab in melanoma, and much more.

This post-meeting report features summaries of a few key topics and trends along with commentary from our analysts on specific presentations. It also includes a compilation of all data events added in conjunction with the meeting.

For the full report, download the PDF version at the top of the page. A full list of ESMO events is also available for download as an Excel file.